About MacuHealth

Founded in 2006 by Frederic Jouhet

Entrepreneur Frederic Jouhet founded the company MacuHealth® with the following goals in mind:

  1. Provide a unique, effective dietary solution to AMD by combining the correct levels of carotenoids found in macular pigment (Lutein, Zeaxanthin and Meso-Zeaxanthin).
  2. Prioritize scientific research and enlist world class scientists to prove the formula’s efficacy and safety through peer-reviewed studies.

MacuHealth Formula

The MacuHealth® with LMZ3 formula contains 10 mg of Lutein (L), 2 mg of Zeaxanthin (Z) and 10 mg of the most potent antioxidant in the macula, Meso-Zeaxanthin (MZ). MacuHealth takes immense pride in having helped to pioneer much of the revolutionary research behind this final critical carotenoid (MZ), and its role in preserving and improving visual function. More recently, the company began supporting the emerging research on the fascinating correlation between carotenoid levels, impaired vision, and cognitive performance.

 

Publications

With over 30 peer reviewed publications that demonstrate the formula’s efficacy, bioavailability and safety, MacuHealth® is at the forefront of preventative treatments for macular disease. The company holds both worldwide exclusivity and a patent on the science-based 10-10-2 formulation. With help from its distribution groups, MacuHealth (MacuShield in Europe) is now the supplement of choice in the fight against AMD and enhancement of visual function worldwide.

 

Partnerships

MacuHealth® proudly accomplished its original objectives and the company is now focusing on a partnership with a likeminded AMD company known as SightRisk®. Developed in Ireland in 2008, SightRisk® is an online analytical tool that allows eye care professionals to assess a person’s risk of developing AMD. SightRisk® analyzes a patient’s answers to questions pertaining to dietary habits, genetics and overall health. It then feeds these answers through an algorithm, weighted and based on thousands of real patient data points, to accurately identify a patient’s risk for AMD. The resulting report provides a line graph that compares current risk to the potential reduced risk after treatment has been implemented. SightRisk® provides invaluable information that enables eye care professionals to monitor, make recommendations, and treat at-risk-individuals earlier. This early intervention can be the pivotal difference in delaying or preventing the onset of eye disease altogether. Learn More at www.sightriskusa.com

Read more about our story, meet the team, or contact us today.